Tina Albertson

Tina Albertson

Company: Lyell Immunopharma

Job title: Chief Medical Officer, Head of Development

Seminars:

Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours 5:30 pm

• Epigenetic reprogramming (Epi-R) results in durable stemness of T-cells • Genetic reprogramming (Gen-R) limits T-cell exhaustion after infusion to reverse the suppressive effects of the tumour microenvironment and continuous antigen stimulation • These technologies are being evaluated in all T-cell modalities, CAR-T cells (CAR), TCR engineered T-cells (TCR), and tumour infiltrating lymphocytes (TIL) productsRead more

day: Day 1 – Track C – Evening

Workshop I: Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours 3:00 pm

Epigenetic reprogramming (Epi-R) results in durable stemness of T-cells Genetic reprogramming (Gen-R) limits T-cell exhaustion after infusion to reverse the suppressive effects of the tumour microenvironment and continuous antigen stimulation These technologies are being evaluated in all T-cell modalities, CAR-T cells (CAR), TCR engineered T-cells (TCR), and tumour infiltrating lymphocytes (TIL) productsRead more

day: Workshop – Track C – Evening

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.